In this case, drug response may depend not only on biomarker detection, and the biomarker may not be valid in all contexts (reduced biomarker specificity): as an example, K-ras is valid as biomarker in colon cancer but not in lung cancer for the detection of an inactive EGFR pathway in treatment with EGFR inhibitors. The gene discussed is KRAS; the disease is lung cancer.